Trial Information

Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions

Official Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of R333 6% Ointment Administered Topically to Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Patients With Active Cutaneous Discoid Lesions

Summary

The purpose of this study is to determine the safety, efficacy and tolerability of topical R333 ointment in Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) patients with active discoid lesions.

Phase: Phase 2

Sponsor: Rigel Pharmaceuticals

Overall Contacts:

Daniel Magilavy, M.D.
650-624-1372
dmagilavy@rigel.com

Locations (15)

Country	State	City	Zip	Facility and Contact
United States	California	Los Angeles	90027	Wallace Rheumatic Study Center Daniel Wallace, MD 310-360-9197 Daniel Wallace, MD Principal Investigator
United States	California	Redwood City	94063	Stanford Dermatology David Fiorentino, MD 650-721-7147 David Fiorentino, MD Principal Investigator
United States	Indiana	South Bend	46601	Memorial Medical Group Clinical Research Institute Nicholas Straniero, MD 574-647-7883 Nicholas Straniero, MD Principal Investigator
United States	New York	Lake Success	11042	North Shore Long Island Health System Richard Furie, MD 516-708-2557 Richard Furie, MD Principal Investigator
United States	New York	New York	10032	Columbia University Medical Center Julian Mackay-Wiggan, MD 212-305-5293 Julian Mackay-Wiggan, MD Principal Investigator
United States	North Carolina	Winston-Salem	27104	Wake Forest University Health Sciences Joseph Jorizzo, MD 336-716-3775 Joseph Jorizzo, MD Principal Investigator
United States	Oklahoma	Oklahoma City	73104	Oklahoma Medical Research Foundation Joan Merrill, MD 405-271-7805 Joan Merrill, MD Principal Investigator
United States	Pennsylvania	Philadelphia	19104	University of Pennsylvania-Dermatology Research Office Victoria Werth, MD 215-898-0168 Victoria Werth, MD Principal Investigator
United States	Texas	Dallas	75231	Metroplex Clinical Research Center Stanley Cohen, MD 214-424-0401 Stanley Cohen, MD Principal Investigator
United States	Texas	Houston	77030	University of Texas Medical School at Houston Adelaide Herbert, MD 713-500-8260 Adelaide Hebert, MD Principal Investigator
United States	Utah	Salt Lake City	84132	University of Utah Department of Dermatology Christopher Hansen, MD 801-581-6477 Christopher Hansen, MD Principal Investigator
United States	Virginia	Norfolk	23507	Virginia Clinical Research, Inc David Pariser, MD 757-625-0151 David Pariser, MD Principal Investigator
Canada	British Columbia	Vancouver	V5Z 4E8	University of British Columbia, Vancouver Dermatology Clinical Trials Unit Jan Dutz, MD 604-875-5296 Jan Dutz, MD Principal Investigator
Canada	Manitoba	Winnipeg	R3C 1R4	Dermadvances Research Jack Toole, MD 204-947-1630 Jack Toole, MD Principal Investigator
Canada	Ontario	Markham	L3P 1A8	Lynderm Research, Inc Charles Lynde, MD 905-471-8011 Charles Lynde, MD Principal Investigator

NCT ID:NCT01597050

Date Last Changed: August 17, 2012